Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb 26:2022:1160000.
doi: 10.1155/2022/1160000. eCollection 2022.

Remarkable Differences in Calcification between the Primary Tumor and Metastatic Lymph Nodes in a Patient with ALK-Positive Non-Small-Cell Lung Cancer

Keeya Sunata  1   2 , Tetsuo Tani  1   3 , Takahiko Ui  1 , Hidehiro Irie  1 , Yohei Funatsu  1 , Hidefumi Koh  1
Affiliations
Case Reports

Remarkable Differences in Calcification between the Primary Tumor and Metastatic Lymph Nodes in a Patient with ALK-Positive Non-Small-Cell Lung Cancer

Keeya Sunata et al. Case Rep Pulmonol. .

Abstract

Calcified bilateral mediastinal lymph nodes are not common in malignant tumors. A 51-year-old woman presented to our hospital with a 20 mm nodule in the lower left lobe of the lung and extensive calcification in the bilateral mediastinal lymph nodes. Computed tomography indicated no calcification of the primary lesion. Immunohistochemical staining and fluorescent in situ hybridization detected an anaplastic lymphoma kinase (ALK) fusion. Treatment with alectinib, an ALK inhibitor, led to a significant reduction in tumor size and calcification in the lymph nodes. This case shows that different degrees of calcification can be associated with malignant tumors and may be reversible in some cases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
CT scan showing the primary lung tumor (a), calcification of the mediastinal lymph nodes before the administration of alectinib (b), and the lymph nodes 4 months after the administration of alectinib (c). White arrow showing subcarinal lymph nodes (b, c). CT: computed tomography.
Figure 2
Figure 2
H&E of primary lung tumor (a) and black arrow showing psammoma body (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. Cancer statistics, 2021. CA: a Cancer Journal for Clinicians . 2021;71(1):7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Ikemura S., Yasuda H., Matsumoto S., et al. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations. Proceedings of the National Academy of Sciences of the United States of America . 2019;116(20):10025–10030. doi: 10.1073/pnas.1819430116. - DOI - PMC - PubMed
    1. Hartman T. E. Radiologic evaluation of the solitary pulmonary nodule. Radiologic Clinics of North America . 2005;43(3):459–65, vii. - PubMed
    1. Hida T., Nokihara H., Kondo M., et al. Alectinib versus crizotinib in patients with _ALK_ -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet . 2017;390(10089):29–39. doi: 10.1016/S0140-6736(17)30565-2. - DOI - PubMed
    1. Parwani A. V., Chan T. Y., Ali S. Z. Significance of psammoma bodies in serous cavity fluid: a cytopathologic analysis. Cancer . 2004;102(2):87–91. doi: 10.1002/cncr.20161. - DOI - PubMed

Publication types

LinkOut - more resources